{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:32:30Z","timestamp":1790191950351,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myelofibrosis (MF) is a clonal haematopoietic disease, with median overall survival for patients with primary MF only 6.5\u00a0years. The most frequent gene mutation found in patients is <jats:italic>JAK2<\/jats:italic><jats:sup>V617F<\/jats:sup>, causing constitutive activation of the kinase and activation of downstream signalling. Fedratinib is an oral selective JAK2 inhibitor. It has shown activity in MF and is well-tolerated, but combination with other therapies is likely needed to achieve clonal remission. Combining a JAK2 inhibitor with an interferon may be synergistic, as haematopoietic cells are activated from quiescence (a typical kinase resistance mechanism) rendering them more sensitive to inhibition.<\/jats:p>\n                <jats:p>Ropeginterferon alfa-2b is a next generation pegylated interferon-\u03b1-2b with high tolerability and clinical activity in patients with MF, however, evidence of tolerability and activity in combination with fedratinib is lacking in this setting. The aim of the FEDORA trial is to assess tolerability, safety, and activity of fedratinib with ropeginterferon alfa-2b in patients with MF who require treatment to justify further investigation in a phase III trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>FEDORA is a single arm, multicentre, open-label, Bayesian phase II trial to assess tolerability, safety, and activity of fedratinib with ropeginterferon alfa-2b aiming to recruit 30 patients. Patients with <jats:italic>JAK2<\/jats:italic><jats:sup>V617F<\/jats:sup> positive primary or secondary MF, who are aged\u2009\u2265\u200918 years, have intermediate-1 with palpable splenomegaly of\u2009&gt;\u20095cm, intermediate-2, or high-risk disease according to the Dynamic International Prognostic Scoring System (DIPSS), and who require treatment are eligible. The primary outcome is tolerability, whereby the combination is deemed intolerable in a patient if drug-related toxicities in the first four months of treatment lead to: either drug being discontinued; delays in treatment exceeding 28 consecutive days; or death. FEDORA uses a within-patient dose escalation regimen to ensure each patient reaches a personalised dose combination that is acceptable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>FEDORA is using a Bayesian trial design and aims to provide evidence of the tolerability, safety, and activity of combining fedratinib with ropeginterferon alfa-2b upon which the decision as to whether a phase III trial is warranted will be based.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT number: 2021\u2013004056-42.<\/jats:p>\n                <jats:p>ISRCTN: 88,102,629.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-024-13383-3","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T03:39:12Z","timestamp":1736480352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Graham","family":"McIlroy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Gaskell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Yafai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Tasker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitsum","family":"Ghebretinsea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Frances","family":"McMullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"13383_CR1","doi-asserted-by":"publisher","unstructured":"Hoffman R, Rondelli D. Biology and treatment of primary myelofibrosis. Hematology Am Soc Hematol Educ Program. 2007:346\u201354. https:\/\/doi.org\/10.1182\/asheducation-2007.1.346","DOI":"10.1182\/asheducation-2007.1.346"},{"issue":"1","key":"13383_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A, Lasho TL, Jimma T, et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. Mayo Clin Proc. 2012;87(1):25\u201333. https:\/\/doi.org\/10.1016\/j.mayocp.2011.11.001.","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"13383_CR3","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1200\/JCO.2012.42.0240","volume":"30","author":"F Cervantes","year":"2012","unstructured":"Cervantes F, Dupriez B, Passamonti F, et al. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol. 2012;30(24):2981\u20137. https:\/\/doi.org\/10.1200\/JCO.2012.42.0240.","journal-title":"J Clin Oncol"},{"issue":"2","key":"13383_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Finke CM, et al. Targeted deep sequencing in primary myelofibrosis. Blood Adv. 2016;1(2):105\u201311. https:\/\/doi.org\/10.1182\/bloodadvances.2016000208.","journal-title":"Blood Adv"},{"issue":"4","key":"13383_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2141.2012.09108.x","volume":"157","author":"C Harrison","year":"2012","unstructured":"Harrison C, Verstovsek S, McMullin MF, et al. Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? Br J Haematol. 2012;157(4):426\u201337. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09108.x.","journal-title":"Br J Haematol"},{"issue":"5","key":"13383_CR6","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","volume":"32","author":"T Barbui","year":"2018","unstructured":"Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018;32(5):1057\u201369. https:\/\/doi.org\/10.1038\/s41375-018-0077-1.","journal-title":"Leukemia"},{"issue":"4","key":"13383_CR7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","volume":"13","author":"G Wernig","year":"2008","unstructured":"Wernig G, Kharas MG, Okabe R, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008;13(4):311\u201320. https:\/\/doi.org\/10.1016\/j.ccr.2008.02.009.","journal-title":"Cancer Cell"},{"issue":"7","key":"13383_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1200\/JCO.2010.32.8021","volume":"29","author":"A Pardanani","year":"2011","unstructured":"Pardanani A, Gotlib JR, Jamieson C, et al. Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol. 2011;29(7):789\u201396. https:\/\/doi.org\/10.1200\/JCO.2010.32.8021.","journal-title":"J Clin Oncol"},{"issue":"5","key":"13383_CR9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","volume":"1","author":"A Pardanani","year":"2015","unstructured":"Pardanani A, Harrison C, Cortes JE, et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015;1(5):643\u201351. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1590.","journal-title":"JAMA Oncol"},{"issue":"7","key":"13383_CR10","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Schaap N, Vannucchi AM, et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 2017;4(7):e317\u201324. https:\/\/doi.org\/10.1016\/S2352-3026(17)30088-1.","journal-title":"Lancet Haematol"},{"issue":"6","key":"13383_CR11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1002\/ajh.25777","volume":"95","author":"CN Harrison","year":"2020","unstructured":"Harrison CN, Schaap N, Vannucchi AM, et al. Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. Am J Hematol. 2020;95(6):594\u2013603. https:\/\/doi.org\/10.1002\/ajh.25777.","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"13383_CR12","doi-asserted-by":"publisher","first-page":"4197","DOI":"10.1182\/blood.V130.Suppl_1.4197.4197","volume":"130","author":"CN Harrison","year":"2017","unstructured":"Harrison CN, Mesa RA, Jamieson C, et al. Case Series of Potential Wernicke\u2019s Encephalopathy in Patients Treated with Fedratinib. Blood. 2017;130(Supplement 1):4197. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.4197.4197.","journal-title":"Blood."},{"issue":"8","key":"13383_CR13","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","volume":"4","author":"A Mullally","year":"2020","unstructured":"Mullally A, Hood J, Harrison C, et al. Fedratinib in myelofibrosis. Blood Adv. 2020;4(8):1792\u2013800. https:\/\/doi.org\/10.1182\/bloodadvances.2019000954.","journal-title":"Blood Adv"},{"issue":"10","key":"13383_CR14","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/modpathol.2015.93","volume":"28","author":"M Pizzi","year":"2015","unstructured":"Pizzi M, Silver RT, Barel A, et al. Recombinant interferon-alpha in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. Mod Pathol. 2015;28(10):1315\u201323. https:\/\/doi.org\/10.1038\/modpathol.2015.93.","journal-title":"Mod Pathol"},{"issue":"1","key":"13383_CR15","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/asheducation.V2012.1.567.3806899","volume":"2012","author":"H Nguyen","year":"2012","unstructured":"Nguyen H, Kiladjian J-J. Is there a role for the use of IFN-\u03b1 in primary myelofibrosis? Hematology. 2012;2012(1):567\u201370. https:\/\/doi.org\/10.1182\/asheducation.V2012.1.567.3806899.","journal-title":"Hematology"},{"issue":"3","key":"13383_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1023\/a:1023668705040","volume":"8","author":"M Chawla-Sarkar","year":"2003","unstructured":"Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis. 2003;8(3):237\u201349. https:\/\/doi.org\/10.1023\/a:1023668705040.","journal-title":"Apoptosis"},{"issue":"11","key":"13383_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","volume":"6","author":"GP Dunn","year":"2006","unstructured":"Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6(11):836\u201348. https:\/\/doi.org\/10.1038\/nri1961.","journal-title":"Nat Rev Immunol"},{"issue":"18","key":"13383_CR18","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1182\/blood-2012-05-432989","volume":"121","author":"A Mullally","year":"2013","unstructured":"Mullally A, Bruedigam C, Poveromo L, et al. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-alpha in a murine model of polycythemia vera. Blood. 2013;121(18):3692\u2013702. https:\/\/doi.org\/10.1182\/blood-2012-05-432989.","journal-title":"Blood"},{"issue":"15","key":"13383_CR19","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","volume":"126","author":"H Gisslinger","year":"2015","unstructured":"Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, et al. Ropeginterferon alfa-2b, a novel IFNalpha-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126(15):1762\u20139. https:\/\/doi.org\/10.1182\/blood-2015-04-637280.","journal-title":"Blood"},{"issue":"3","key":"13383_CR20","doi-asserted-by":"publisher","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","volume":"7","author":"H Gisslinger","year":"2020","unstructured":"Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. Lancet Haematol. 2020;7(3):e196\u2013208. https:\/\/doi.org\/10.1016\/S2352-3026(19)30236-4.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"13383_CR21","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1182\/blood-2018-99-119268","volume":"132","author":"H Gisslinger","year":"2018","unstructured":"Gisslinger H, Gisslinger B, Schalling M, et al. Effect of Ropeginterferon Alfa-2b in Prefibrotic Primary Myelofibrosis. Blood. 2018;132(Supplement 1):3029. https:\/\/doi.org\/10.1182\/blood-2018-99-119268.","journal-title":"Blood."},{"issue":"Supplement 1","key":"13383_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/blood-2020-138934","volume":"136","author":"JM Palmer","year":"2020","unstructured":"Palmer JM, Kosiorek HE, Dueck AC, et al. Ropeginterferon Demonstrates Safety and Efficacy in Myelofibrosis: Pilot Study Results. Blood. 2020;136(Supplement 1):23. https:\/\/doi.org\/10.1182\/blood-2020-138934.","journal-title":"Blood."},{"issue":"7240","key":"13383_CR23","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nature07815","volume":"458","author":"MA Essers","year":"2009","unstructured":"Essers MA, Offner S, Blanco-Bose WE, et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature. 2009;458(7240):904\u20138. https:\/\/doi.org\/10.1038\/nature07815.","journal-title":"Nature"},{"issue":"9","key":"13383_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398. https:\/\/doi.org\/10.1056\/NEJMoa1110556.","journal-title":"N Engl J Med"},{"issue":"5","key":"13383_CR25","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","volume":"4","author":"RA Mesa","year":"2017","unstructured":"Mesa RA, Vannucchi AM, Mead A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. Lancet Haematol. 2017;4(5):e225\u201336. https:\/\/doi.org\/10.1016\/S2352-3026(17)30027-3.","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"13383_CR26","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1182\/blood-2018-99-110785","volume":"132","author":"J-J Kiladjian","year":"2018","unstructured":"Kiladjian J-J, Soret-Dulphy J, Resche-Rigon M, et al. Ruxopeg, a Multi-Center Bayesian Phase 1\/2 Adaptive Randomized Trial of the Combination of Ruxolitinib and Pegylated Interferon Alpha 2a in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis. Blood. 2018;132(Supplement 1):581. https:\/\/doi.org\/10.1182\/blood-2018-99-110785.","journal-title":"Blood."},{"issue":"9","key":"13383_CR27","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.3324\/haematol.2019.235648","volume":"105","author":"AL S\u00f8rensen","year":"2020","unstructured":"S\u00f8rensen AL, Mikkelsen SU, Knudsen TA, et al. Ruxolitinib and interferon-alpha2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study. Haematologica. 2020;105(9):2262\u201372. https:\/\/doi.org\/10.3324\/haematol.2019.235648.","journal-title":"Haematologica"},{"issue":"9","key":"13383_CR28","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703\u20138. https:\/\/doi.org\/10.1182\/blood-2009-09-245837.","journal-title":"Blood"},{"key":"13383_CR29","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, G\u00f8tzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. https:\/\/doi.org\/10.1136\/bmj.e7586.","journal-title":"BMJ"},{"issue":"8","key":"13383_CR30","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395\u20138. https:\/\/doi.org\/10.1182\/blood-2013-03-488098.","journal-title":"Blood"},{"key":"13383_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.leukres.2017.05.012","volume":"59","author":"C Gwaltney","year":"2017","unstructured":"Gwaltney C, Paty J, Kwitkowski VE, et al. Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. Leuk Res. 2017;59:26\u201331. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.012.","journal-title":"Leuk Res"},{"issue":"8","key":"13383_CR32","first-page":"1128","volume":"90","author":"J Thiele","year":"2005","unstructured":"Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005;90(8):1128\u201332.","journal-title":"Haematologica."},{"key":"13383_CR33","unstructured":"Cancer Therapy Evaluation Program (CTEP). National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 2017 [Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Last Accessed: 20-Oct-2023"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13383-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13383-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T04:30:55Z","timestamp":1736483455000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13383-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13383"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13383-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial is being performed in accordance with the recommendations guiding physicians in biomedical research involving human subjects, adopted by the 18th World Medical Association General Assembly, Helsinki, Finland, 1964, amended by the 48th WMA General Assembly, Somerset West, Republic of South Africa, October 1996.The protocol (currently v4.0, dated 10-May-2023) was initially approved by the Yorkshire & The Humber\u2014Leeds West Research Ethics Committee on 07-Jan-2022 (Ref. 21\/YH\/0300). Approval was also granted by the Medicines and Healthcare Products Regulatory Agency on 28-Jan-2022. The FEDORA Trial Office coordinates and communicates protocol modifications to all relevant parties.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MFM has participated in advisory boards for Novartis, BMS, Incyte and GSK, and has received speakers bureau from Novatis, AOP Health, and Incyte. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}